Svetomir N Markovic

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. pmc Expansion of CD16-negative natural killer cells in the peripheral blood of patients with metastatic melanoma
    Shernan G Holtan
    Division of Hematology, Department of Medicine, Mayo Clinic Graduate School of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Clin Dev Immunol 2011:316314. 2011
  2. pmc Aromatase inhibitors, estrogens and musculoskeletal pain: estrogen-dependent T-cell leukemia 1A (TCL1A) gene-mediated regulation of cytokine expression
    Mohan Liu
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Breast Cancer Res 14:R41. 2012
  3. pmc Therapy for metastatic melanoma: the past, present, and future
    Laura Finn
    Division of Hematology and Oncology, Mayo Clinic Florida, 4500 San Pablo Road, Jacksonville, FL 32224, USA
    BMC Med 10:23. 2012
  4. pmc CRP identifies homeostatic immune oscillations in cancer patients: a potential treatment targeting tool?
    Brendon J Coventry
    Department of Surgery and Tumour Immunology Laboratory, University of Adelaide, Royal Adelaide Hospital, South Australia, Australia
    J Transl Med 7:102. 2009
  5. ncbi request reprint Metastatic malignant melanoma
    S N Markovic
    Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    G Ital Dermatol Venereol 144:1-26. 2009
  6. ncbi request reprint Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization
    Svetomir N Markovic
    Melanoma Study Group of the Mayo Clinic Cancer Center, Mayo Clinic, Rochester, MN 55905, USA
    Am J Clin Oncol 29:352-60. 2006
  7. pmc A reproducible method for the enumeration of functional (cytokine producing) versus non-functional peptide-specific cytotoxic T lymphocytes in human peripheral blood
    S N Markovic
    Hematology Oncology Department, Mayo Clinic, Rochester, MN 55905, USA
    Clin Exp Immunol 145:438-47. 2006
  8. ncbi request reprint A phase II study of bortezomib in the treatment of metastatic malignant melanoma
    Svetomir N Markovic
    Melanoma Study Group, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA
    Cancer 103:2584-9. 2005
  9. pmc A dose-escalation study of aerosolized sargramostim in the treatment of metastatic melanoma: an NCCTG Study
    Svetomir N Markovic
    Melanoma Study Group, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Am J Clin Oncol 31:573-9. 2008
  10. ncbi request reprint A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma
    Svetomir N Markovic
    Department of Oncology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Am J Clin Oncol 30:303-9. 2007

Research Grants

  1. B7-DC Cross-linking antibody immunotherapy
    Svetomir Markovic; Fiscal Year: 2007

Detail Information

Publications123 found, 100 shown here

  1. pmc Expansion of CD16-negative natural killer cells in the peripheral blood of patients with metastatic melanoma
    Shernan G Holtan
    Division of Hematology, Department of Medicine, Mayo Clinic Graduate School of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Clin Dev Immunol 2011:316314. 2011
    ..81, P = .015)). These findings suggest the possibility of exploring anti-TGF-β therapy to restore NK function in melanoma...
  2. pmc Aromatase inhibitors, estrogens and musculoskeletal pain: estrogen-dependent T-cell leukemia 1A (TCL1A) gene-mediated regulation of cytokine expression
    Mohan Liu
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Breast Cancer Res 14:R41. 2012
    ..In the present study, we set out to determine whether these SNPs might influence cytokine expression and effect more widely, and, if so, to explore the mechanism of TCL1A-related AI-induced side effects...
  3. pmc Therapy for metastatic melanoma: the past, present, and future
    Laura Finn
    Division of Hematology and Oncology, Mayo Clinic Florida, 4500 San Pablo Road, Jacksonville, FL 32224, USA
    BMC Med 10:23. 2012
    ..In this review we will discuss the advantages and limitations of the two new approved agents, current clinical trials designed to overcome these limitations, and future clinical trials that we feel hold the most promise...
  4. pmc CRP identifies homeostatic immune oscillations in cancer patients: a potential treatment targeting tool?
    Brendon J Coventry
    Department of Surgery and Tumour Immunology Laboratory, University of Adelaide, Royal Adelaide Hospital, South Australia, Australia
    J Transl Med 7:102. 2009
    ..This knowledge might also open the way for improved timing of treatment(s) for improved clinical efficacy...
  5. ncbi request reprint Metastatic malignant melanoma
    S N Markovic
    Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    G Ital Dermatol Venereol 144:1-26. 2009
    ..Herein we review the state-of-the-art in metastatic melanoma diagnostics and therapeutics with particular emphasis on multi-disciplinary clinical management...
  6. ncbi request reprint Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization
    Svetomir N Markovic
    Melanoma Study Group of the Mayo Clinic Cancer Center, Mayo Clinic, Rochester, MN 55905, USA
    Am J Clin Oncol 29:352-60. 2006
    ....
  7. pmc A reproducible method for the enumeration of functional (cytokine producing) versus non-functional peptide-specific cytotoxic T lymphocytes in human peripheral blood
    S N Markovic
    Hematology Oncology Department, Mayo Clinic, Rochester, MN 55905, USA
    Clin Exp Immunol 145:438-47. 2006
    ..The simplicity and reliability of the assay provide for high-throughput applications and automation. The utility and application of this method are discussed...
  8. ncbi request reprint A phase II study of bortezomib in the treatment of metastatic malignant melanoma
    Svetomir N Markovic
    Melanoma Study Group, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA
    Cancer 103:2584-9. 2005
    ..Bortezomib is a proteasome inhibitor with manageable clinical toxicity and laboratory evidence of anti-melanoma activity. Therefore, it was considered for clinical testing in patients with metastatic melanoma...
  9. pmc A dose-escalation study of aerosolized sargramostim in the treatment of metastatic melanoma: an NCCTG Study
    Svetomir N Markovic
    Melanoma Study Group, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Am J Clin Oncol 31:573-9. 2008
    ..To improve the clinical and immunologic efficacy of therapy without compromising patient safety, we performed a further dose escalation trial in patients with metastatic melanoma...
  10. ncbi request reprint A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma
    Svetomir N Markovic
    Department of Oncology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Am J Clin Oncol 30:303-9. 2007
    ..We conducted a phase II trial evaluating the clinical efficacy of ABT-510 and its effects on biomarkers of angiogenesis and immunity in patients with metastatic melanoma (MM)...
  11. ncbi request reprint Overlapping human leukocyte antigen class I/II binding peptide vaccine for the treatment of patients with stage IV melanoma: evidence of systemic immune dysfunction
    Esteban Celis
    Mayo Clinic Cancer Center, Rochester, Minnesota 55905, USA
    Cancer 110:203-14. 2007
    ..In this report, the authors present the results from a clinical trial that evaluated the safety and immunologic efficacy of the MPS160 vaccine in patients with metastatic melanoma...
  12. ncbi request reprint Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin lymphoma: a prospective study
    Luis F Porrata
    Division of Hematology, Department of Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Biol Blood Marrow Transplant 14:807-16. 2008
    ..This is the first study confirming the ALC-15 survival role prospectively and identifying NK cells as the key ALC-15 lymphocyte subset affecting survival after APHSCT...
  13. ncbi request reprint Absolute lymphocyte count predicts therapeutic efficacy of rituximab therapy in follicular lymphomas
    Deepti Behl
    Division of Hematology Department Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Br J Haematol 137:409-15. 2007
    ..89 x 10(9)/l (5/39, 13%) (P < 0.0001). Multivariate analysis showed ALC to be an independent predictor for TTP. This study supports our hypothesis that a higher ALC predicts longer TTP following rituximab therapy...
  14. doi request reprint Stimulatory effects of CpG oligodeoxynucleotide on dendritic cell-based immunotherapy of colon cancer in CEA/HLA-A2 transgenic mice
    Asim Saha
    Department of Internal Medicine, University of Cincinnati Medical Center, Cincinnati, OH, USA
    Int J Cancer 124:877-88. 2009
    ..These results provide evidence that vaccination with antigen-pulsed DC with CpG ODN as adjuvant can lead to effective tumor regression and long-term survival in a murine model of colon carcinoma...
  15. doi request reprint Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in nodular lymphocyte-predominant Hodgkin lymphoma
    Luis F Porrata
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Br J Haematol 157:321-30. 2012
    ..ALC/AMC-DX is a low cost, already standarized, biomarker to predict clinical outcomes in NLPHL...
  16. doi request reprint A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group study, N0775
    Lisa A Kottschade
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Cancer 119:586-92. 2013
    ..Increasing evidence shows chemotherapy in combination with vascular endothelial growth factor (VEGF) inhibition is a clinically active therapy for patients with metastatic melanoma (MM)...
  17. ncbi request reprint AMD3100 affects autograft lymphocyte collection and progression-free survival after autologous stem cell transplantation in non-Hodgkin lymphoma
    Shernan G Holtan
    Department of Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Clin Lymphoma Myeloma 7:315-8. 2007
    ..AMD3100, a CXCR4 antagonist, mobilizes CD34+ stem cells in patients with NHL undergoing ASCT. We sought to study the impact of AMD3100 on A-ALC collection in patients with NHL undergoing ASCT...
  18. doi request reprint Predicting survival for diffuse large B-cell lymphoma patients using baseline neutrophil/lymphocyte ratio
    Luis F Porrata
    Division of Hematology Department of Medicine, Mayo College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 85:896-9. 2010
    ..This study suggests that baseline N/L ratio at diagnosis is a simple, inexpensive,standardized prognostic factor to assess clinical outcomes in DLBCL patients treated with R-CHOP...
  19. ncbi request reprint Interleukin 15 promotes antigen-independent in vitro expansion and long-term survival of antitumor cytotoxic T lymphocytes
    Jun Lu
    Department of Immunology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Clin Cancer Res 8:3877-84. 2002
    ..The present findings have practical implications for the propagation of antigen-specific T-cell lines in vitro and could be useful for expansion of therapeutic T cells for adoptive transfer...
  20. ncbi request reprint Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade
    Eduardo Davila
    Department of Immunology, Mayo Clinic and Mayo Graduate School, Rochester, Minnesota 55905, USA
    Cancer Res 63:3281-8. 2003
    ..These findings bear clinical significance for the design of peptide-based therapeutic vaccines for human cancer patients...
  21. ncbi request reprint Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma
    L F Porrata
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Blood 98:579-85. 2001
    ..In conclusion, ALC is correlated with clinical outcome and requires further study. (Blood. 2001;98:579-585)..
  22. doi request reprint The absolute monocyte count is associated with overall survival in patients newly diagnosed with follicular lymphoma
    Ryan A Wilcox
    Department of Internal Medicine, Division of Hematology Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI 48109 5948, USA
    Leuk Lymphoma 53:575-80. 2012
    ..These results further support the central role of non-neoplastic myeloid-lineage cells in follicular lymphoma biology...
  23. pmc Interleukin-15 affects patient survival through natural killer cell recovery after autologous hematopoietic stem cell transplantation for non-Hodgkin lymphomas
    Luis F Porrata
    Division of Hematology, Department of Medicine and Blood and Marrow Program, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Clin Dev Immunol 2010:914945. 2010
    ..7, P < .0001) NK-15. Multivariate analysis showed only NK-15 as a prognostic factor for survival, suggesting that the survival benefit observed by IL-15 is most likely mediated by enhanced NK cell recovery post-APHSCT...
  24. pmc Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A
    Domingo G Perez
    Metro Minnesota Community Clinical Oncology Program, St Louis Park, Minnesota, USA
    Cancer 115:119-27. 2009
    ..Therefore, in patients with metastatic melanoma, the combination of chemotherapy with an agent that specifically targets VEGF might be able to control tumor growth and progression more effectively than chemotherapy alone...
  25. ncbi request reprint Absolute lymphocyte count at the time of first relapse predicts survival in patients with diffuse large B-cell lymphoma
    Luis F Porrata
    Division of Hematology Department of Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Am J Hematol 84:93-7. 2009
    ..ALC-R was an independent prognostic factor for OS [RR = 0.4, P < 0.01] and PFS [RR = 0.5, P < 0.005]. ALC-R predicts survival suggesting that host immunity is an important variable predicting survival in first relapsed DLBCL...
  26. doi request reprint Brain metastases from melanoma: is there a role for concurrent temozolomide in addition to whole brain radiation therapy?
    Steven E Schild
    Department of Radiation Oncology, Mayo Clinic, Scottsdale, AZ 85259, USA
    Am J Clin Oncol 33:633-6. 2010
    ..This study was performed to evaluate the addition of temozolomide (TMZ) to whole brain radiotherapy (WBRT) for brain metastases from melanoma...
  27. ncbi request reprint Malignant melanoma in the 21st century, part 2: staging, prognosis, and treatment
    Svetomir N Markovic
    Division of Hematology, College of Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 82:490-513. 2007
    ..Although much work remains to be done to improve the survival of patients with melanoma, clinically meaningful results seem within reach...
  28. pmc A study of paclitaxel, carboplatin, and bortezomib in the treatment of metastatic malignant melanoma: a phase 2 consortium study
    Gary A Croghan
    Department of Medical Oncology, Melanoma Study Group, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Cancer 116:3463-8. 2010
    ..A phase 1 trial of this 3-drug combination reported that 6 of 28 patients treated with bortezomib followed by paclitaxel and carboplatin achieved a partial response (including 2 of 5 patients with metastatic melanoma)...
  29. ncbi request reprint Multiepitope Trojan antigen peptide vaccines for the induction of antitumor CTL and Th immune responses
    Jun Lu
    Department of Immunology and Cancer Center, Mayo College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    J Immunol 172:4575-82. 2004
    ....
  30. ncbi request reprint Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion
    Haidong Dong
    Department of Immunology, Mayo Clinic, Rochester, Minnesota, USA
    Nat Med 8:793-800. 2002
    ..These findings have implications for the design of T cell-based cancer immunotherapy...
  31. ncbi request reprint Immunomodulation of early engrafted natural killer cells with interleukin-2 and interferon-alpha in autologous stem cell transplantation
    L F Porrata
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Bone Marrow Transplant 28:673-80. 2001
    ..IL-2 and IFN-alpha up-regulated NK cell activity at 14 days post ASCT. They may be useful as immunomodulators as early as 14 days post ASCT to eradicate or control minimal residual disease...
  32. doi request reprint New-onset lymphopenia assessed during routine follow-up is a risk factor for relapse postautologous peripheral blood hematopoietic stem cell transplantation in patients with diffuse large B-cell lymphoma
    Luis F Porrata
    Division of Hematology Department of Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Biol Blood Marrow Transplant 16:376-83. 2010
    ..0 x 10(9)/L (N=122) (P < .0001). This study suggests that new-onset lymphopenia measured by ALC can be used as marker to assess risk of DLBCL relapse during routine follow-up for after APHSCT...
  33. ncbi request reprint The effect of absolute lymphocyte count recovery kinetics on survival after autologous stem cell transplantation for non-Hodgkin's lymphoma
    Yinlee Yoong
    Division of Hematology, Department of Internal Medecine, Mayo Clinic, Rochester, MN 55909, USA
    Leuk Lymphoma 46:1287-94. 2005
    ..0001). Multivariate analysis demonstrated K-ALC recovery post-ASCT to be an independent prognostic indicator for OS and PFS. These data support our hypothesis that the K-ALC post-ASCT is associated with clinical outcome in NHL...
  34. pmc Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphoma
    Luis F Porrata
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Haematologica 97:262-9. 2012
    ..We, therefore, studied whether the peripheral blood absolute lymphocyte count/absolute monocyte count ratio at diagnosis affects survival in classical Hodgkin's lymphoma...
  35. pmc Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas
    Thomas E Witzig
    Division of Hematology, Department of Medicine, Mayo Clinic College of Medicine and Mayo Foundation, Rochester, MN, USA
    Blood 118:4882-9. 2011
    ..In view of its excellent toxicity profile and novel mechanism of action, further studies in combination with other agents appear warranted. This trial is registered at www.clinicaltrials.gov as #NCT00082888...
  36. pmc A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group Study, N057E(1)
    Lisa A Kottschade
    Mayo Clinic Rochester, Rochester, Minnesota 55905, USA
    Cancer 117:1704-10. 2011
    ..ABI-007 is an albumin-bound formulation of paclitaxel that has demonstrated single-agent activity against metastatic melanoma...
  37. pmc Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphoma
    Matthew J Maurer
    Mayo Clinic College of Medicine and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 29:1620-6. 2011
    ..This assay has prognostic value in plasma cell proliferative disorders. There are limited data on serum FLC in B-cell malignancies...
  38. ncbi request reprint Direct cross-priming by th lymphocytes generates memory cytotoxic T cell responses
    Richard Kennedy
    Department of Immunology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    J Immunol 174:3967-77. 2005
    ..These findings suggest a novel role of Th cells as pAPC for the development of memory immune responses...
  39. ncbi request reprint Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen
    Asim Saha
    Department of Internal Medicine, University of Cincinnati Medical Center, Cincinnati, Ohio 45267 0509, USA
    Cancer Res 67:2881-92. 2007
    ..These results suggest the potential use of this vaccination strategy for future clinical applications...
  40. doi request reprint Multiple roles for CD4+ T cells in anti-tumor immune responses
    Richard Kennedy
    Mayo Vaccine Research Group, Mayo Clinic College of Medicine, Rochester, MN, USA
    Immunol Rev 222:129-44. 2008
    ..These unconventional roles for Th lymphocytes, which require direct cell-to-cell communication with CTLs, are clear examples of how versatile these immunoregulatory cells are...
  41. pmc Recognition of six-transmembrane epithelial antigen of the prostate-expressing tumor cells by peptide antigen-induced cytotoxic T lymphocytes
    David A Rodeberg
    Department of Immunology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Clin Cancer Res 11:4545-52. 2005
    ..Also because STEAP-292.2L is a more immunogenic peptide able to induce CTL recognition of these STEAP-containing tumors and may have potential as an antitumor peptide vaccine...
  42. ncbi request reprint Absolute lymphocyte count predicts overall survival in follicular lymphomas
    Mustaqeem Siddiqui
    Department of Medicine, Mayo Clinic College of Medicine, Rochester, MN, USA
    Br J Haematol 134:596-601. 2006
    ..677, P < 0.0001). These data suggest a critical role of FL patients' immune status at diagnosis on survival...
  43. doi request reprint Regional immunity in melanoma: immunosuppressive changes precede nodal metastasis
    Aaron S Mansfield
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Mod Pathol 24:487-94. 2011
    ..These immunologic changes may explain the successful metastasis of melanoma in the midst of the immune environment of the sentinel lymph node, and lend insights into the mechanisms of lymphatic metastases in other solid malignancies...
  44. ncbi request reprint Effectiveness of second line salvage chemotherapy with ifosfamide, carboplatin, and etoposide in patients with relapsed diffuse large B-cell lymphoma not responding to cis-platinum, cytosine arabinoside, and dexamethasone
    Lijo Simpson
    Division of Hematology, Department of Medicine, Rochester, MN, USA
    Leuk Lymphoma 48:1332-7. 2007
    ..Patients with progressive disease on DHAP should be considered for alternative salvage regimens or experimental therapy...
  45. ncbi request reprint Identification of naturally processed helper T-cell epitopes from prostate-specific membrane antigen using peptide-based in vitro stimulation
    Hiroya Kobayashi
    Department of Immunology, Mayo Clinic, Rochester, Minnesota55905, USA
    Clin Cancer Res 9:5386-93. 2003
    ..The present studies were performed with the purpose of identifying HTL epitopes for prostate-specific membrane antigen (PSMA) for the optimization of vaccines for prostate cancer...
  46. ncbi request reprint The dose of infused lymphocytes in the autograft directly correlates with clinical outcome after autologous peripheral blood hematopoietic stem cell transplantation in multiple myeloma
    L F Porrata
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
    Leukemia 18:1085-92. 2004
    ..Multivariate analysis demonstrated A-ALC as an independent prognostic indicator for OS and TTP. These results indicate that an infused dose of autograft lymphocytes significantly impacts clinical outcome post-APHSCT in MM...
  47. pmc Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies
    Shaji K Kumar
    Divisions of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN, USA
    Invest New Drugs 31:1201-6. 2013
    ..Sorafenib (a VEGFR and multi-targeted kinase inhibitor) and Bortezomib (a proteasome inhibitor) have clinical antineoplastic activities as single agents, and combine synergistically in preclinical models...
  48. ncbi request reprint Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma
    Ravi D Rao
    Department of Medical Oncology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Cancer 106:375-82. 2006
    ..Patients with metastatic melanoma (MM) have very few therapy options. Based on reports of responses to paclitaxel and carboplatin (PC), 31 patients with MM were treated with PC...
  49. ncbi request reprint The International Prognostic Index predicts outcome after histological transformation of low-grade non-Hodgkin lymphoma
    Ivana N M Micallef
    Divison of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Leuk Lymphoma 47:1794-9. 2006
    ..In conclusion, tIPI at the time of histological transformation is an important predictor of OS. A time to transformation > 4 years from diagnosis is associated with better OS...
  50. pmc Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia
    Shanique Palmer
    Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Br J Haematol 141:607-14. 2008
    ..These characteristics can be modified and continued evaluation of immunomodulatory drugs, vaccination strategies and cellular therapies to delay/prevent disease progression are warranted...
  51. ncbi request reprint In-transit melanoma: an individualized approach
    Travis E Grotz
    Department of Surgery, Mayo Clinic, Rochester, Minnesota, USA
    Oncology (Williston Park) 25:1340-8. 2011
    ..Herein we present our institutional treatment algorithm, which allows for individualization based on the patient's presentation...
  52. doi request reprint Pilot study of granulocyte-macrophage colony-stimulating factor and interleukin-2 as immune adjuvants for a melanoma peptide vaccine
    Matthew S Block
    Department of Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Melanoma Res 21:438-45. 2011
    ..The increase in T regulatory cells associated with interleukin-2 treatment suggests that interleukin-2 may be immunosuppressive in this setting...
  53. doi request reprint Combination cytokine therapy inhibits tumor growth by generation of tumor-specific T-cell responses in a murine melanoma model
    Amer N Kalaaji
    Department of Dermatology, Mayo Clinic, Rochester, MN 55905, USA
    Cytokine 49:287-93. 2010
    ..These results support potential clinical trials of the low-dose cytokine combination as adjuvant therapy for melanoma...
  54. doi request reprint Prediction of survival using absolute lymphocyte count for newly diagnosed patients with multiple myeloma: a retrospective study
    Hilmi Ege
    Division of Hematology Department of Medicine, Mayo Clinic College of Medicine, Rochester, MN, USA
    Br J Haematol 141:792-8. 2008
    ..This study showed that, in newly diagnosed MM, ALC is an independent prognostic factor for OS, suggesting a significant role of host immune status in the survival of MM...
  55. pmc Timing of autologous stem cell transplantation from last chemotherapy affects lymphocyte collection and survival in non-Hodgkin lymphoma
    Shernan G Holtan
    Division of Internal Medicine Department of Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Br J Haematol 133:628-33. 2006
    ..0025, respectively). Multivariate analysis demonstrated TILC to be an independent prognostic indicator for OS and PFS. These findings suggest that the immune status of the host at the time of aphaeresis may predict survival after ASCT...
  56. pmc Cancer and pregnancy: parallels in growth, invasion, and immune modulation and implications for cancer therapeutic agents
    Shernan G Holtan
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 84:985-1000. 2009
    ..The knowledge gained from analyzing similarities and differences between the physiologic state of pregnancy and the pathologic state of cancer could lead to identification of new potential targets for cancer therapeutic agents...
  57. doi request reprint Absolute monocyte/lymphocyte count prognostic score is independent of immunohistochemically determined cell of origin in predicting survival in diffuse large B-cell lymphoma
    Luis F Porrata
    Division of Hematology, Mayo Clinic, Rochester, MN, USA
    Leuk Lymphoma 53:2159-65. 2012
    ..The AMC/ALC score was able to further stratify DLBCL clinical outcomes by COO. The AMC/ALC score was independent of COO and added to its ability to identify patients with high-risk disease...
  58. ncbi request reprint Fluctuation of systemic immunity in melanoma and implications for timing of therapy
    Alexey A Leontovich
    Department of Health Science Research, Mayo Clinic, Rochester, MN 55901, USA
    Front Biosci (Elite Ed) 4:958-75. 2012
    ..Individualized conventional chemotherapy delivery by synchronizing treatment with pre-existing patient-specific biorhythms may improve clinical outcomes in metastatic melanoma...
  59. ncbi request reprint T-cell epitope peptide vaccines
    Sherine F Elsawa
    Department of Immunology, Mayo Clinic, Rochester, MN, USA
    Expert Rev Vaccines 3:563-75. 2004
    ..This article will review the use of peptide-based vaccines for the treatment of cancer by inducing antitumor T-lymphocyte responses...
  60. ncbi request reprint Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia
    D Behl
    Department of Medicine, Mayo College of Medicine, Rochester, MN 55905, USA
    Leukemia 20:29-34. 2006
    ..Multivariate analysis demonstrated ALC > or = 500 cells/microl at all time points to be an independent prognostic factor for survival. Our data suggest a critical role of lymphocyte (immune) recovery on survival after IC in AML...
  61. ncbi request reprint Prolonged survival associated with early lymphocyte recovery after autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer
    L F Porrata
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Bone Marrow Transplant 28:865-71. 2001
    ..In conclusion, ALC > or = 500 cells/microl on day 15 post-ASCT was associated with significantly better survival in patients with metastatic breast cancer, suggesting the importance of early immune recovery post-ASCT in these patients...
  62. ncbi request reprint Apheresis instrument settings influence infused absolute lymphocyte count affecting survival following autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin's lymphoma: the need to optimize instrument setting and define a lymphocyte
    R Katipamula
    Division of Transfusion Medicine, Mayo Clinic, Rochester, MN 55902, USA
    Bone Marrow Transplant 37:811-7. 2006
    ..These data suggest that apheresis instrument settings should be optimized to collect CD34(+) cells as well as an A-ALC target, with direct impact on survival post-APHSCT...
  63. ncbi request reprint Therapeutic options in patients with lymphoma and severe liver dysfunction
    Irene M Ghobrial
    Division of Hematology and Internal Medicine, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 79:169-75. 2004
    ....
  64. pmc Melanoma brain metastases and vemurafenib: need for further investigation
    Nicole M Rochet
    Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 87:976-81. 2012
    ..Further, we discuss possible mechanisms responsible for the suboptimal central nervous system response observed in these patients and alternative therapies for patients with melanoma metastatic to the brain...
  65. ncbi request reprint An organ system based approach to prognosis in advanced melanoma
    Shernan G Holtan
    Department of Medicine, Division of Hematology, Mayo Clinic Graduate School of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Front Biosci (Elite Ed) 4:2823-33. 2012
    ..A subset of melanoma patients appear to lack an organized immune response to the tumor, which portends a poor prognosis...
  66. doi request reprint Emerging therapies for melanoma
    Rajini Katipamula
    Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Expert Rev Anticancer Ther 8:553-60. 2008
    ..The focus of this review is to summarize the emerging therapies and investigational agents in the treatment of melanoma over the last 5 years...
  67. ncbi request reprint Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis
    Luis F Porrata
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Clin Cancer Res 11:1210-8. 2005
    ..The relationship of ALC-15 with clinical outcomes in primary systemic amyloidosis is unknown...
  68. pmc B7-DC cross-linking restores antigen uptake and augments antigen-presenting cell function by matured dendritic cells
    Suresh Radhakrishnan
    Department of Immunology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Proc Natl Acad Sci U S A 102:11438-43. 2005
    ..By stimulating DCs with two distinct activation signals, a previously unrecognized phenotype exhibiting augmented antigen-presenting functions was obtained...
  69. ncbi request reprint Immune reconstitution after autologous hematopoietic stem cell transplantation
    L F Porrata
    Department of Oncology, Mayo Cinic, Rochester, Minn. 55905, USA
    Mayo Clin Proc 76:407-12. 2001
    ....
  70. ncbi request reprint Infused peripheral blood autograft absolute lymphocyte count correlates with day 15 absolute lymphocyte count and clinical outcome after autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin's lymphoma
    L F Porrata
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Bone Marrow Transplant 33:291-8. 2004
    ..0001, respectively). Multivariate analysis demonstrated A-ALC to be an independent prognostic indicator for OS and PFS. These data support our hypothesis that ALC-15 and survival are dependent upon the dose of infused A-ALC in NHL...
  71. ncbi request reprint Immunomodulatory effects of sex hormones: requirements for pregnancy and relevance in melanoma
    Elizabeth Ann L Enninga
    Mayo Graduate School, Mayo Clinic, Rochester, MN
    Mayo Clin Proc 89:520-35. 2014
    ..Mimicking the maternal immune response to pregnancy, especially in late gestation, might aid in design of better therapies to reconstitute endogenous antitumor immunity and improve survival...
  72. doi request reprint Vulvar and vaginal melanoma: case series and review of current management options including neoadjuvant chemotherapy
    Jo Marie Tran Janco
    Division of Gynecologic Surgery, Mayo Clinic, 200 1st St SW, Rochester, MN 55905, USA
    Gynecol Oncol 129:533-7. 2013
    ..We report our experience with vulvar (Vu) and vaginal (Va) melanoma, with review of surgical and adjuvant therapy guidelines and description of our use of neoadjuvant therapy in selected cases...
  73. doi request reprint Regional lymphatic immunity in melanoma
    Travis E Grotz
    Division of Surgery, Mayo Clinic, Rochester, Minnesota 55905, USA
    Melanoma Res 22:9-18. 2012
    ..Herein we provide a succinct summary of the current progress in this field in order to guide future investigations...
  74. pmc Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines
    Stephen M Ansell
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 85:824-33. 2010
    ..Autologous stem cell transplant should be considered in all eligible patients with relapsed disease...
  75. ncbi request reprint Malignant melanoma in the 21st century, part 1: epidemiology, risk factors, screening, prevention, and diagnosis
    Svetomir N Markovic
    Division of Hematology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 82:364-80. 2007
    ..Part 2 (which will appear in the April 2007 issue) will review melanoma staging, prognosis, and treatment...
  76. pmc Lack of effective T-lymphocyte response to the PAX3/FKHR translocation area in alveolar rhabdomyosarcoma
    David A Rodeberg
    Department of Surgery, Mayo Clinic, 200 First Street, SW, Rochester, MN, 55905, USA
    Cancer Immunol Immunother 54:526-34. 2005
    ..Our study was directed at identifying antigenic T-lymphocyte epitopes at the PAX3/FKHR translocation point area...
  77. ncbi request reprint Augmentation of T cell levels and responses induced by androgen deprivation
    Anja C Roden
    Department of Urology, Comprehensive Cancer Center, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    J Immunol 173:6098-108. 2004
    ..Such alterations induced by androgen deprivation may have implications for enhancing immune responses to immunotherapy and for accelerating the recovery of the immune system following chemotherapy...
  78. pmc Getting peptide vaccines to work: just a matter of quality control?
    Esteban Celis
    Department of Immunology, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Clin Invest 110:1765-8. 2002
  79. ncbi request reprint Recognition of prostate tumor cells by cytotoxic T lymphocytes specific for prostate-specific membrane antigen
    Jun Lu
    Department of Immunology, Mayo Graduate School, and Mayo Cancer Center, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Res 62:5807-12. 2002
    ..These results underline the importance of demonstrating antitumor reactivity of peptide-induced CTLs for the selection of epitopes destined to become immunotherapeutic for prostate cancer...
  80. pmc Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors
    Pilar Nava-Parada
    Department of Immunology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Cancer Res 67:1326-34. 2007
    ..e., epitope spreading). These results suggest that similar strategies should be followed for conducting clinical studies in patients...
  81. doi request reprint The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma
    R A Wilcox
    Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 25:1502-9. 2011
    ..This prognostic score was independent of the IPI and added to its ability to identify high-risk patients...
  82. pmc Evidence of systemic Th2-driven chronic inflammation in patients with metastatic melanoma
    Wendy K Nevala
    Division of Hematology, Department of Internal Medicine, Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA
    Clin Cancer Res 15:1931-9. 2009
    ..To understand this discrepancy, we attempted to define immune homeostasis of 209 patients with melanoma across stages of disease relative to normal controls...
  83. ncbi request reprint Extracorporeal photopheresis and adjuvant aerosolized granulocyte-macrophage colony-stimulating factor for Sézary syndrome
    Saskia A Bouwhuis
    Department of Dermatology, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 77:197-200. 2002
    ..It produced clinical improvement and decreased the number of circulating Sézary cells in a previously ECP-refractory patient...
  84. pmc Day 100 Peripheral Blood Absolute Lymphocyte/Monocyte Ratio and Survival in Classical Hodgkin's Lymphoma Postautologous Peripheral Blood Hematopoietic Stem Cell Transplantation
    Luis F Porrata
    Division of Hematology, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Bone Marrow Res 2013:658371. 2013
    ..P < 0.0001). Day ALC/AMC ratio was an independent predictor for OS and PFS. Thus, Day 100 ALC/AMC ratio is a simple biomarker that can help to assess clinical outcomes from day 100 post-APBHSCT in cHL patients...
  85. pmc Phase II trial of intravenous administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma
    Evanthia Galanis
    Mayo Clinic, Rochester, Minnesota 55905, USA
    Mol Ther 20:1998-2003. 2012
    ..Based on preclinical data showing synergy with taxane and platinum compounds, a phase II combination trial in metastatic melanoma patients is ongoing...
  86. doi request reprint Novel therapeutics for the treatment of metastatic melanoma
    Aaron S Mansfield
    Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Future Oncol 5:543-57. 2009
    ..Herein, we review some of the recent advances in novel therapeutic developments for the treatment of metastatic melanoma...
  87. ncbi request reprint Inhibition of EBV-induced lymphoproliferation by CD4(+) T cells specific for an MHC class II promiscuous epitope
    Ryusuke Omiya
    Department of Immunology, Mayo Clinic, Rochester, MN 55905, USA
    J Immunol 169:2172-9. 2002
    ..These results are relevant for the design of a simple, inexpensive and widely applicable peptide-based vaccine to prevent PTLD in solid organ transplant patients...
  88. pmc Antigen-independent acquisition of MHC class II molecules by human T lymphocytes
    Anita H Undale
    Department of Immunology, Mayo Clinic, Rochester, MN, USA
    Int Immunol 16:1523-33. 2004
    ..These results suggest that T cells are able to interact with other T cells to regulate immune responses by presenting MHC peptide complexes that have been snatched away from nearby APC...
  89. doi request reprint Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma
    L F Porrata
    Division of Hematology, Department of Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Leukemia 24:1343-9. 2010
    ..96 x 10(9)/l (N=46) (P<0.0001). This study suggests that lymphopenia measured by ALC can be used as a marker to assess risk of DLBCL relapse during routine follow-up after standard chemotherapy...
  90. ncbi request reprint Aerosol granulocyte macrophage-colony stimulating factor: a low toxicity, lung-specific biological therapy in patients with lung metastases
    P M Anderson
    Department of Pediatrics, Mayo Clinic, Rochester, Minnesota 55905, USA
    Clin Cancer Res 5:2316-23. 1999
    ..Aerosol delivery of GM-CSF is feasible, safe, and possibly effective. Aerosol cytokine delivery may achieve effective immunological activation against cancer in the lung and is worthy of further study...
  91. doi request reprint Increased bowel toxicity in patients treated with a vascular endothelial growth factor inhibitor (VEGFI) after stereotactic body radiation therapy (SBRT)
    Brandon M Barney
    Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA
    Int J Radiat Oncol Biol Phys 87:73-80. 2013
    ..We explored the incidence of serious bowel injury (SBI) in patients treated with SBRT with or without vascular endothelial growth factor inhibitor (VEGFI) therapy...
  92. ncbi request reprint Phase II trial of KW2189 in patients with advanced malignant melanoma
    Svetomir N Markovic
    Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA
    Am J Clin Oncol 25:308-12. 2002
    ..In summary, the lack of significant antitumor activity of KW-2189 and its associated toxicity suggest that further testing of this regimen in patients with stage IV melanoma is not warranted...
  93. ncbi request reprint Personalized therapy for metastatic melanoma: could timing be everything?
    Roxana S Dronca
    Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA
    Future Oncol 8:1401-6. 2012
    ....
  94. ncbi request reprint Early lymphocyte recovery post-autologous haematopoietic stem cell transplantation is associated with better survival in Hodgkin's disease
    Luis F Porrata
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Br J Haematol 117:629-33. 2002
    ..5 x 10(9) cells/l ("not yet reached" versus 42 months, P < 0.0001; 57 versus 15 months, P < 0.002 respectively). Thus, ALC recovery on day 15 post ASCT in HD is associated with better survival and requires further study...
  95. doi request reprint Use of various offset settings in the Fenwal Amicus during hematopoietic progenitor cell collection to increase lymphocyte yield and reduce cross-cellular contamination
    Edwin A Burgstaler
    Division of Transfusion Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Clin Apher 25:301-9. 2010
    ..Autologous HPC collection focus has been CD34+ cell yield but product content of other cells is important for patient survival, complications, and resource utilization...
  96. pmc Circulating serologic and molecular biomarkers in malignant melanoma
    Shanique R Palmer
    Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 86:981-90. 2011
    ....
  97. ncbi request reprint Malignant basomelanocytic tumor manifesting as metastatic melanoma
    Lori A Erickson
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
    Am J Surg Pathol 28:1393-6. 2004
    ..A second population of cells was strongly immunoreactive for keratin (wide-spectrum polyclonal antibody) and BerEp4. To our knowledge, this is the first description of a malignant basomelanocytic tumor complicated by metastatic melanoma...
  98. ncbi request reprint Management of multifocal primary cutaneous CD30 anaplastic large cell lymphoma
    James M Shehan
    Department of Dermatology, Mayo Clinic, Rochester, MN 55905, USA
    J Am Acad Dermatol 51:103-10. 2004
    ..Newer treatments, including anti-CD30 monoclonal antibodies, show promise. However, further study is needed to develop optimal therapeutic strategies...
  99. ncbi request reprint Treatment of brain metastases from melanoma
    Robert R McWilliams
    Division of Medical Oncology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 78:1529-36. 2003
    ..Chemotherapy may be gaining a role with newer agents that penetrate the blood-brain barrier. Combined modality therapy appears to be the future direction of treatment of multiple metastases...
  100. doi request reprint Differential response of human and mouse dendritic cells to VEGF determines interspecies discrepancies in tumor-mediated TH1/TH2 polarity shift
    Matthew S Block
    Department of Oncology, Mayo Clinic, Rochester, Minnesota 55920, USA
    Clin Cancer Res 17:1776-83. 2011
    ..This is due, at least in part, to effects of VEGF on antigen presenting cell (APC) function. We therefore compared immune polarity changes in mouse models of cancer with those seen in human patients...

Research Grants3

  1. B7-DC Cross-linking antibody immunotherapy
    Svetomir Markovic; Fiscal Year: 2007
    ..If successful, this "proof-of-principle" clinical trial will justify further development of B7-DC XAb as a cancer therapeutic with potential universal application for all malignant disorders. ..